Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status

•New therapeutic strategies in OC have led to a patient-tailored medicine.•PARPis, as new agents, have improved the maintenance-therapy landscape in ROC.•The effectiveness of PARPis in BRCA-mutated platinum sensitive ROC is confirmed.•PARPis are effective in BRCA wild type and whole population, to a lesser extent.•PARPis are effective regardless of BRCA mutational status.